All In Biotech

Drug Trial Radar · NCT05548556

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Feb 7, 2023

Primary completion

May 2, 2025

Study completion Oct 9, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Conditions

  • Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions

  • PlaceboDrug

    Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)

  • RO7204239Drug

    Participants will receive SC RO7204239 Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in contractile muscle volume (CMV) of quadriceps femoris muscles as assessed by magnetic resonance imaging (MRI) bilaterallyTime frame: Week 52
  2. Percentage of participants with adverse events (AEs)Time frame: Up to 2.5 years

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Irvine Medical Center (UCIMC)

    Orange, California

  • Regents of the University of Colorado

    Aurora, Colorado

  • University of Kansas Medical Center

    Fairway, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Rigshospitalet

    København Ø, Denmark

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, Italy

  • Asst Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy

  • National Hospital for Neurology and Neurosurgery,

    London, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.